Search
for
Sort by
Research 121–150 of 1000+
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- SAT-288 Successful Virilization of a PAIS Patient with a Missense Mutation In The Ligand-binding Domain Of The Androgen Receptor with Combined High-dose Testosterone and Aromatase Inhibitor
- Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
- Estrogenic Potential of 2-Alkyl-4-(thio)chromenone 6-<i>O</i>-Sulfamates: Potent Inhibitors of Human Steroid Sulfatase
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Enzyme Inhibitors from Gorgonians and Soft Corals
- JAK-centric explainable few-shot gene-expression diagnosis framework for alopecia via MultiPLIER priors and relation-style set-to-set comparison
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- Lupus erythematosus: systemic and cutaneous manifestations
- Management of Sexual Dysfunction in Postmenopausal Breast Cancer Patients Taking Adjuvant Aromatase Inhibitor Therapy
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Phospholipase A2 Is Required for PIN-FORMED Protein Trafficking to the Plasma Membrane in the<i>Arabidopsis</i>Root
- Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231
- Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer
- Management of congenital ichthyoses: European guidelines of care, part two
- Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
- Role of janus kinase inhibitors in the treatment of alopecia areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Deciphering principles of morphogenesis from temporal and spatial patterns on the integument